INVA Quote, Financials, Valuation and Earnings

Disc Medicine has a net margin of -52.56% compared to Innoviva's net margin of --. Innoviva's return on equity of -8.85% beat Disc Medicine's return on equity of --.

Innoviva has a consensus price target of $55.00, signalling upside risk potential of 205.39%. On the other hand Disc Medicine has an analysts' consensus of $99.20 which suggests that it could grow by 116.93%. Given that Innoviva has higher upside potential than Disc Medicine, analysts believe Innoviva is more attractive than Disc Medicine.

Innoviva has a beta of 0.353, which suggesting that the stock is 64.673% less volatile than S&P 500. In comparison Disc Medicine has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Disc Medicine pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $88.6M, which are larger than Disc Medicine quarterly revenues of --. Innoviva's net income of -$46.6M is lower than Disc Medicine's net income of -$34.1M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Disc Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.60x versus -- for Disc Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -52.56% compared to Innoviva's net margin of -6391.57%. Innoviva's return on equity of -8.85% beat Janux Therapeutics's return on equity of -11.37%.

Innoviva has a consensus price target of $55.00, signalling upside risk potential of 205.39%. On the other hand Janux Therapeutics has an analysts' consensus of $84.12 which suggests that it could grow by 271.89%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

Innoviva has a beta of 0.353, which suggesting that the stock is 64.673% less volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $88.6M, which are larger than Janux Therapeutics quarterly revenues of $439K. Innoviva's net income of -$46.6M is lower than Janux Therapeutics's net income of -$23.5M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.60x versus 98.69x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -52.56% compared to Innoviva's net margin of -49.65%. Innoviva's return on equity of -8.85% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Innoviva has a consensus price target of $55.00, signalling upside risk potential of 205.39%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 42.86%. Given that Innoviva has higher upside potential than NovaBay Pharmaceuticals, analysts believe Innoviva is more attractive than NovaBay Pharmaceuticals.

Innoviva has a beta of 0.353, which suggesting that the stock is 64.673% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $88.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Innoviva's net income of -$46.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Innoviva's price-to-earnings ratio is 98.63x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.60x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -52.56% compared to Innoviva's net margin of --. Innoviva's return on equity of -8.85% beat Theriva Biologics's return on equity of --.

Innoviva has a consensus price target of $55.00, signalling upside risk potential of 205.39%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1150%. Given that Theriva Biologics has higher upside potential than Innoviva, analysts believe Theriva Biologics is more attractive than Innoviva.

Innoviva has a beta of 0.353, which suggesting that the stock is 64.673% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $88.6M, which are larger than Theriva Biologics quarterly revenues of --. Innoviva's net income of -$46.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.60x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.